Percutaneous needle biopsy of the liver is an important procedure in diagnosing liver disease in infants as it often provides diagnostic information not obtainable by other methods.' 2 The technique has been widely used in adults for over 30 years. Recent reports have confirmed the low incidence of complications of liver biopsy as long as results of coagulation tests are normal.5 Percutaneous liver biopsy was first reported in children in the late 1950s '9 and is regarded as safe in this age group.10
The safety of this procedure in infants, however, is sometimes questioned. No recent series to our knowledge specifically examines the mortality and morbidity in children less than 1 year old.
We studied the safety of percutaneous liver biopsy in infants and report the morbidity in children aged 1 The liver biopsy needle was 1-2 mm in diameter. The number of attempts at biopsy required to obtain an acceptable specimen was recorded when reported. The histological diagnosis was noted. (Table 2) . Three had a drop in haemoglobin concentration, for which two were given transfusions. Only one of these was symptomatic. A further patient with haemoglobin concentration before the procedure of 8-7 g/dl had an episode of hypotension after the biopsy; no treatment was required, and we did not know whether this reflected bleeding or sensitivity to the sedation. One child developed a small subcutaneous haematoma at the biopsy site; it resolved without treatment.
Patients with a potentially higher than average risk of morbidity after liver biopsy include very small infants, those with anaemia, and, as shown in previous studies in adults, those with thombocytopenia, abnormal coagulation test results, or severe ascites. Twenty six of the 27 children weighing S 3 kg had no complications; one infant, who weighed 2-7 kg, had a drop in haemoglobin concentration. In the entire series there were 21 patients with haemoglobin concentrations < 9-5 g/dl; none experienced any difficulties except the child with transient hypotension. No complications occurred in seven patients with platelet counts ranging from 60 to 90 x 109/1 or in one patient with a platelet count of 48 x 109/l. Three children had abnormal results of coagulation tests (prothrombin time > 14 seconds; partial thromboplastin time > 47 seconds). Two were given vitamin K or fresh frozen plasma before the biopsy and one received no supplementation: none had a complication. Three children had obvious One infant underwent biopsy twice: neonatal hepatitis diagnosed on first, and extrahepatic biliary atresia on second, biopsy. life threatening complications in a series of 210 biopsies performed in 166 patients, of whom 67 were aged 1 year or less and 24 were aged 1 week to 2 months."1 Three minor complications were reLiver biopsy in infants 903 ported in the entire series, but the ages of the patients were not stated. In a prospective study of the risks of certain procedures in children Ament found a rate of complications of 4% in 584 liver biopsies performed at 25 centres in 1978.22 These complications included bleeding, pneumothorax, and pain; clinical details including ages of the patients, number of infants with and without complications, condition of patients, and biopsy technique were not given.22
In infants the indications for liver biopsy are similar to those in adults. Severe cholestasis is not a contraindication to liver biopsy in this age group, although in most cases ultrasound examination of the liver will have been performed before biopsy to exclude the presence of cysts or large bile lakes likely to be punctured by the biopsy needle. Likewise liver congestion per se is not a contraindication. Any In adults the theoretical risk of this procedure has been determined by pooling individual series of liver biopsies. Data on infants from other studies in which the Menghini method was used are difficult to interpret because of insufficient information, and if these are added to our series they raise the total number of infants to about 250, which is still too small to eliminate the f error entirely.9"1 Our data from one centre with only one biopsy technique suggest that percutaneous liver biopsy is safe in infants. The rate of minor complications was 2-7%. Recently there has been some enthusiasm for performing liver biopsies in adults as an outpatient procedure.4 2S We do not think that our data can be extended to support a policy of routine outpatient liver biopsy for infants.
The decision about whether to perform a liver biopsy in an infant should be based on the usefulness of the histological information to be gained as well as on technical considerations. Delay in diagnosis of liver disease in infants can have serious consequences. Liver biopsy specimens are prepared at this hospital for histochemical studies and light and electron microscopic examination. We obtained diagnostically important information in 83% of cases.
We conclude that a percutaneous liver biopsy performed by the Menghini technique is safe even in small infants. The patient should have normal coagulation, and there should be no other major contraindications to the procedure. Ultrasound examination of the liver should be performed before liver biopsy. Potentially vascular lesions should not be biopsied percutaneously. The relative risks and benefits of percutaneous liver biopsy in infants weighing < 2 kg should be carefully considered. Young age or small body size, however, are not in themselves high risk exclusion criteria for this procedure.
